An understanding of the mechanisms underlying NET-mediated inflammation will empower clinicians to target therapies that can mitigate disease activity & improve outcomes in patients with lupus.
Lupus Update: Findings from the Latest Phase 3 Clinical Trials
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
Bringing Lupus into the Light
With more than 350 research abstracts on systemic lupus erythematosus, lupus nephritis and related conditions accepted for presentation at ACR Convergence 2024, we’re happy to announce that Graciela S. Alarcón, MD, MPH, has accepted the monumental task of reviewing the abstracts and identifying those most likely to make a difference to clinical practice or lead…
Meet the 2024 Lupus Insight Prize Honorees
Marko Radic, PhD, & Georg Schett, MD, were awarded the 2024 Lupus Insight Prize for advances in CAR-T cell therapy.
How to Manage Lupus Nephritis: A New Guideline Introduced
A new guideline, the 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis, is being introduced at ACR Convergence 2024 on Monday, Nov. 18. In the session, Lisa Sammaritano, MD, professor of clinical medicine at Weill Cornell Medicine and Hospital for Special Surgery, New York, will discuss the guideline development process and…
Building a More Equitable Future in Lupus Care
The Dubois Memorial Lecture at ACR Convergence 2024 on Nov. 16 will be delivered by Candace Feldman, MD, MPH, ScD. Dr. Feldman is a rheumatologist and social epidemiology researcher at Brigham and Women’s Hospital/Harvard Medical School, Boston. Her lecture, Building a More Equitable Future in Lupus Care and Outcomes, will discuss the persistent and profound…
Personalize Your Pediatric Lupus Care
On Nov. 16, the ACR Convergence 2024 session Toward Personalized Medicine in Pediatric Lupus will present important recent findings in the pathophysiology of pediatric lupus. Virginia Pascual, MD, is program director of an NIAID-funded Autoimmunity Center of Excellence and a NIAMS-funded Center for Lupus Research at Weill Cornell Medical College, New York. Her laboratory is…
Lupus: Closer to a Cause?
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
B Cell-Depleting Therapy in SLE
“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
Anti-Nuclear Antibodies & Nuclear Molecules in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that primarily affects young women and causes a wide range of inflammatory manifestations. Its hallmark is the production of antibodies to components of the cell nucleus (anti-nuclear antibodies [ANAs]). …
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 43
- Next Page »